Initial characteristics of patients randomized to receive mercaptopurine or thioguanine in maintenance treatment
. | Mercaptopurine . | Thioguanine . |
|---|---|---|
| No. of patients | 238 | 236 |
| Risk group | ||
| Low risk | 121 | 116 |
| High risk | 117 | 120 |
| Sex | ||
| Male | 135 | 138 |
| Female | 103 | 98 |
| Age, y | ||
| Median | 4.8 | 4.7 |
| Range | 1.0-17.8 | 1.0-16.4 |
| Immunophenotype | ||
| Pro-B-ALL | 2 | 9 |
| Common ALL | 167 | 149 |
| Pre-B-ALL | 37 | 41 |
| T-ALL | 32 | 37 |
| WBC × 109/L | ||
| Median | 8.6 | 9.8 |
| Range | 0.4-773 | 0.6-750 |
| Philadelphia chromosome positive | 0 | 0 |
. | Mercaptopurine . | Thioguanine . |
|---|---|---|
| No. of patients | 238 | 236 |
| Risk group | ||
| Low risk | 121 | 116 |
| High risk | 117 | 120 |
| Sex | ||
| Male | 135 | 138 |
| Female | 103 | 98 |
| Age, y | ||
| Median | 4.8 | 4.7 |
| Range | 1.0-17.8 | 1.0-16.4 |
| Immunophenotype | ||
| Pro-B-ALL | 2 | 9 |
| Common ALL | 167 | 149 |
| Pre-B-ALL | 37 | 41 |
| T-ALL | 32 | 37 |
| WBC × 109/L | ||
| Median | 8.6 | 9.8 |
| Range | 0.4-773 | 0.6-750 |
| Philadelphia chromosome positive | 0 | 0 |